Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05932069 · ClinicalTrials.gov registry record · NA
Active AMD Study to Improve Function in Veterans
A NA study of Age-related Macular Degeneration (AMD), sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05932069 is a NA study of Age-related Macular Degeneration (AMD) that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 70 participants, below the 101,912-participant average among 7 other Age-related Macular Degeneration (AMD) trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05932069, a NA study of Age-related Macular Degeneration (AMD), is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Age Related Macular Degeneration (AMD) is the leading cause of vision loss among Veterans aged 50 years and older. AMD also adversely affects mortality, physical and cognitive functioning, and activities of daily living. These debilitations negatively impact quality of life for US Veterans. Unfortunately, there are no cures and few treatments. With the increase in the aging Veteran population and the increasing prevalence of AMD, it is imperative to identify and implement strategies to limit the functional burden of AMD. To address this growing challenge, the investigators propose to test the impact of a proven exercise intervention, stationary bicycling (spinning), on visual and non-visual negative health outcomes in AMD. The work in several retinal degeneration mouse models shows that aerobic exercise significantly preserves retinal morphology and function and visual acuity. Even more exciting, the investigators' preliminary work with older Veterans with and without AMD suggests that spin cycling modestly but significantly benefits visual acuity in aged Veterans. Based on this work, the investigators propose to implement a 6-month synchronous, online group spin cycling program for Veterans with AMD, evaluating effects on physical, cognitive, and visual outcomes.
Conditions Studied
Interventions
- BEHAVIORAL SPIN
- BEHAVIORAL Non-aerobic, stretching/balance intervention Control
Study Locations (1)
Georgia
- Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2028-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05932069
The ClinicalTrials.gov registry entry for NCT05932069 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101,912-participant average among 7 other Age-related Macular Degeneration (AMD) trials with a reported enrollment target (100% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration (AMD) appearing as the primary indexed condition, and to 2 interventions - of which SPIN is the first listed.
NCT05932069 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05932069 about?
NCT05932069 is a clinical study titled "Active AMD Study to Improve Function in Veterans". Age Related Macular Degeneration (AMD) is the leading cause of vision loss among Veterans aged 50 years and older. AMD also adversely affects mortality, physical and cognitive functioning, and activities of daily living. These debilitations negatively impact quality of life for US Veterans. Unfortun...
What is the current status of trial NCT05932069?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-03-01. Estimated completion is 2028-08-31.
What conditions does trial NCT05932069 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration (AMD).
What interventions are being tested in trial NCT05932069?
The interventions under investigation include: SPIN (BEHAVIORAL), Non-aerobic, stretching/balance intervention Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT05932069?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05932069 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration (AMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
RECRUITING
-
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RECRUITING · Phase 2
-
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
COMPLETED
-
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
COMPLETED
-
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.